LCTX (Lineage Cell Therapeutics) Short Interest


LCTX Lineage Cell Therapeutics Inc LCTX
78 GF Score
Price $1.27
GF Value $1.33
Valuation Fairly Valued
! 4 Warning Signs
View Full Analysis

What is Lineage Cell Therapeutics Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

LCTX vs FATE, ABEO, RCKT: Short Interest Comparison

For the Biotechnology subindustry, Lineage Cell Therapeutics's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Lineage Cell Therapeutics Short Interest vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Lineage Cell Therapeutics's Short Interest distribution charts can be found below:

* The bar in red indicates where Lineage Cell Therapeutics's Short Interest falls into.


LCTX
78GF Score
Lineage Cell Therapeutics Inc LCTX
Short Interest is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Lineage Cell Therapeutics (LCTX) Overvalued in 2026?

Based on GuruFocus' analysis, Lineage Cell Therapeutics stock appears to be undervalued. The current stock price of $1.27 is trading 4.5% below its estimated GF Value™ of $1.33. GuruFocus considers Lineage Cell Therapeutics to be Fairly Valued.

Key valuation signals for LCTX:

  • Short Interest:
  • GF Value™: $1.33 vs. price of $1.27 (4.5% below fair value)
  • GF Score™: 78/100 with 4 warning signs

No single metric tells the full story. See the LCTX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Lineage Cell Therapeutics Business Description

Other Exchanges LCTX:IsraelBT3:Germany
Address 2173 Salk Avenue, Suite 200, Carlsbad, CA, USA, 92008
Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline currently includes: OpRegen, OPC1, ReSonance, ILT1, RND1, PNC1, and LCT-CON. Its programs are based on its proprietary, in-house, cell-based manufacturing platform, which it call AlloSCOPE (Allogeneic, Scalable, Consistent, Off-the-shelf, Pluripotent Cell Engineering), and supported by its associated development, formulation, manufacturing, and delivery capabilities. The AlloSCOPE platform is a proprietary differentiation and production modality from which, a single, well-characterized pluripotent cell line can create a stable current Good Manufacturing Practice, master cell bank.
78GF Score

Get the complete analysis for LCTX

Short Interest is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.27
Price
$1.33
GF Value